Additional information
| Plant Capacity | 300 Kgs./Day |
|---|---|
| Land & Building | (Area 1500 sq.mt.) Rs. 1.19 Cr. |
| Plant & Machinery | Rs. 1.08 Cr. |
| W.C. for 2 Months | Rs. 95 Lacs |
| Total Capital Investment | Rs. 3.54 Cr. |
| Rate of Return | 34% |
| Break Even Point | 51% |
The project report includes Present Market Position and Expected Future Demand, Market Size, Statistics, Trends, SWOT Analysis and Forecasts. Report provides a comprehensive analysis from industry covering detailed reporting and evaluates the position of the industry by providing insights to the SWOT analysis of the industry.
We can prepare PROJECT REPORT as per your INVESTMENT PLAN for BANK LOAN REQUIREMENT and INDUSTRY ANALYSIS. All reports are prepared by highly qualified consultants and verified by a panel of experts.
The Chinese herb mixture “Ma Huang” has been used empirically by native physicians for more than 5000 years. “Ma Huang”, which contains ophedrine, has also been widely used in U.S.S.R.in the treatment of various disorders. While the my driatic activity of the alkaloid ephedrine was first demonstrated in 1887 by Miura, the use of ephedrine as a my driatic enjoyed only a passing vogue. International interest in the drug was stimulated in 1924 by the classical investigations of Chen and Schmidt, who reported its cardiovascular effects, its similarity to epinephrine, and its absorption from the intestinal tract. Ephedrine (1-phenyl-2-methylaminopropanol) (C6 H5 CH COH) CH (NH. CH3). CH3 is optically active (Levorotatory) form, which is white to colourless granules, pieces or crystals, hygroscopic in nature and gradually decomposes on exposure to light.It is
soluble in water, alcohol, ether, chloroform and oils. Its major use in medicine is as bronchodilator.
DETAILED FEASIBILITY REPORT COVERS:
| Plant Capacity | 300 Kgs./Day |
|---|---|
| Land & Building | (Area 1500 sq.mt.) Rs. 1.19 Cr. |
| Plant & Machinery | Rs. 1.08 Cr. |
| W.C. for 2 Months | Rs. 95 Lacs |
| Total Capital Investment | Rs. 3.54 Cr. |
| Rate of Return | 34% |
| Break Even Point | 51% |